Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 30 (12), 1210-6

Protective Efficacy of in Vitro Synthesized, Specific mRNA Vaccines Against Influenza A Virus Infection

Affiliations

Protective Efficacy of in Vitro Synthesized, Specific mRNA Vaccines Against Influenza A Virus Infection

Benjamin Petsch et al. Nat Biotechnol.

Abstract

Despite substantial improvements, influenza vaccine production-and availability-remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.

Comment in

Similar articles

See all similar articles

Cited by 86 PubMed Central articles

See all "Cited by" articles

References

    1. Clin Pharmacol Ther. 2007 Dec;82(6):745-9 - PubMed
    1. Methods Mol Med. 2006;127:23-40 - PubMed
    1. Nat Biotechnol. 2006 Nov;24(11):1377-83 - PubMed
    1. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3877-82 - PubMed
    1. Berl Munch Tierarztl Wochenschr. 2010 Jul-Aug;123(7-8):286-92 - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources

Feedback